The pharmaceutical company Stada in the Czech Republic increased its turnover by 37 % y/y in 2020. This was stated by Stada Pharma CZ CEO Tomáš Mihál. The result was also achieved thanks to the acquisition of the manufacturer of dietary supplements Walmark. Other significant contracts include the purchase of part of GSK's consumer portfolio and former Takeda brands in Russia and the former CIS area. Strada's global revenues exceeded EUR 3bn (nearly CZK 79bn; +6%). The company closed seven acquisitions and more than 80 licensing agreements. Its EBITDA increased by 15 % to EUR 713m (approximately CZK 18.7bn).
Prepared by the team of foreign office CzechTrade Chicago.